Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 34

1.

Postoperative Concurrent Chemoradiotherapy Versus Postoperative Radiotherapy in High-Risk Cutaneous Squamous Cell Carcinoma of the Head and Neck: The Randomized Phase III TROG 05.01 Trial.

Porceddu SV, Bressel M, Poulsen MG, Stoneley A, Veness MJ, Kenny LM, Wratten C, Corry J, Cooper S, Fogarty GB, Collins M, Collins MK, Macann AMJ, Milross CG, Penniment MG, Liu HY, King MT, Panizza BJ, Rischin D.

J Clin Oncol. 2018 May 1;36(13):1275-1283. doi: 10.1200/JCO.2017.77.0941. Epub 2018 Mar 14.

PMID:
29537906
2.

Phase 1 in the development of a patient-reported measure to quantify perceived inconvenience of radiotherapy: generation of issues.

Sundaresan P, Milross CG, Stockler MR, Costa DS, King MT.

Qual Life Res. 2016 Sep;25(9):2361-6. doi: 10.1007/s11136-016-1265-y. Epub 2016 Mar 15.

PMID:
26980419
3.

Barriers to radiotherapy utilisation in New South Wales Australia: Health professionals' perceptions of impacting factors.

Sundaresan P, King MT, Stockler MR, Costa DS, Milross CG.

J Med Imaging Radiat Oncol. 2015 Aug;59(4):535-41; quiz 542-4. doi: 10.1111/1754-9485.12334. Epub 2015 Jun 15.

PMID:
26076378
4.

What is access to radiation therapy? A conceptual framework and review of influencing factors.

Sundaresan P, Stockler MR, Milross CG.

Aust Health Rev. 2016 Feb;40(1):11-18. doi: 10.1071/AH14262. Review.

PMID:
26072910
5.

Factors influencing the use of RT in NSW: a qualitative study exploring consumer and health professional perspectives.

Sundaresan P, Milross CG, Smith A, Evans A, Stockler MR, King MT.

J Med Imaging Radiat Oncol. 2014 Oct;58(5):625-32. doi: 10.1111/1754-9485.12198. Epub 2014 Jun 19.

PMID:
24945988
6.

Phase 3 trial of domiciliary humidification to mitigate acute mucosal toxicity during radiation therapy for head-and-neck cancer: first report of Trans Tasman Radiation Oncology Group (TROG) 07.03 RadioHUM study.

Macann A, Fua T, Milross CG, Porceddu SV, Penniment M, Wratten C, Krawitz H, Poulsen M, Tang CI, Morton RP, Hay KD, Thomson V, Bell ML, King MT, Fraser-Browne CL, Hockey HU.

Int J Radiat Oncol Biol Phys. 2014 Mar 1;88(3):572-9. doi: 10.1016/j.ijrobp.2013.11.226.

PMID:
24521675
7.

Are radiation oncologists aware of health literacy among people with cancer treated with radiotherapy?

Smith SK, Petrak LM, Dhillon HM, Taylor J, Milross CG.

Eur J Cancer Care (Engl). 2014 Jan;23(1):111-20. doi: 10.1111/ecc.12111. Epub 2013 Aug 19.

PMID:
23957463
8.

Supporting patients with low health literacy: what role do radiation therapists play?

Smith SK, Zhu Y, Dhillon HM, Milross CG, Taylor J, Halkett G, Zilliacus E.

Support Care Cancer. 2013 Nov;21(11):3051-61. doi: 10.1007/s00520-013-1875-7. Epub 2013 Jun 28.

PMID:
23812495
9.

Combination antiretroviral therapy as treatment for human immunodeficiency virus-associated mucosa-associated lymphoid tissue type lymphoma of the nasopharynx.

Varma R, Carroll SL, Jacobson IV, Milross CG, Post JJ.

Intern Med J. 2011 May;41(5):437-8. doi: 10.1111/j.1445-5994.2011.02480.x. No abstract available.

PMID:
21605299
10.

Metastatic head and neck cutaneous squamous cell carcinoma: defining a low-risk patient.

Ebrahimi A, Clark JR, Lorincz BB, Milross CG, Veness MJ.

Head Neck. 2012 Mar;34(3):365-70. doi: 10.1002/hed.21743. Epub 2011 Apr 5.

PMID:
21472887
11.

Predicting the prognosis of oral squamous cell carcinoma after first recurrence.

Kernohan MD, Clark JR, Gao K, Ebrahimi A, Milross CG.

Arch Otolaryngol Head Neck Surg. 2010 Dec;136(12):1235-9. doi: 10.1001/archoto.2010.214.

PMID:
21173373
12.

Lymph node ratio as an independent prognostic factor in oral squamous cell carcinoma.

Ebrahimi A, Clark JR, Zhang WJ, Elliott MS, Gao K, Milross CG, Shannon KF.

Head Neck. 2011 Sep;33(9):1245-51. doi: 10.1002/hed.21600. Epub 2010 Oct 21.

PMID:
20967874
13.

Human papillomavirus predicts outcome in oropharyngeal cancer in patients treated primarily with surgery or radiation therapy.

Hong AM, Dobbins TA, Lee CS, Jones D, Harnett GB, Armstrong BK, Clark JR, Milross CG, Kim J, O'Brien CJ, Rose BR.

Br J Cancer. 2010 Nov 9;103(10):1510-7. doi: 10.1038/sj.bjc.6605944. Epub 2010 Oct 19.

14.

Use of cyclin D1 in conjunction with human papillomavirus status to predict outcome in oropharyngeal cancer.

Hong AM, Dobbins TA, Lee CS, Jones D, Fei J, Clark JR, Armstrong BK, Harnett GB, Milross CG, Tran N, Peculis LD, Ng C, Milne AG, Loo C, Hughes LJ, Forstner DF, O'Brien CJ, Rose BR.

Int J Cancer. 2011 Apr 1;128(7):1532-45. doi: 10.1002/ijc.25479. Epub 2010 May 25.

15.

Squamous cell carcinoma of the oropharynx in Australian males induced by human papillomavirus vaccine targets.

Hong AM, Grulich AE, Jones D, Lee CS, Garland SM, Dobbins TA, Clark JR, Harnett GB, Milross CG, O'Brien CJ, Rose BR.

Vaccine. 2010 Apr 26;28(19):3269-72. doi: 10.1016/j.vaccine.2010.02.098. Epub 2010 Mar 10.

PMID:
20226244
16.

Predicting the pattern of regional metastases from cutaneous squamous cell carcinoma of the head and neck based on location of the primary.

Ebrahimi A, Moncrieff MD, Clark JR, Shannon KF, Gao K, Milross CG, O'Brien CJ.

Head Neck. 2010 Oct;32(10):1288-94. doi: 10.1002/hed.21332.

PMID:
20091686
17.

Characterization of childhood acute lymphoblastic leukemia xenograft models for the preclinical evaluation of new therapies.

Liem NL, Papa RA, Milross CG, Schmid MA, Tajbakhsh M, Choi S, Ramirez CD, Rice AM, Haber M, Norris MD, MacKenzie KL, Lock RB.

Blood. 2004 May 15;103(10):3905-14. Epub 2004 Feb 5.

PMID:
14764536
18.

The nonobese diabetic/severe combined immunodeficient (NOD/SCID) mouse model of childhood acute lymphoblastic leukemia reveals intrinsic differences in biologic characteristics at diagnosis and relapse.

Lock RB, Liem N, Farnsworth ML, Milross CG, Xue C, Tajbakhsh M, Haber M, Norris MD, Marshall GM, Rice AM.

Blood. 2002 Jun 1;99(11):4100-8.

PMID:
12010813
19.

Patient demographics may influence white coat preferences.

Dancer JK, Lewis CR, Milross CG.

Med J Aust. 2001 Aug 20;175(4):228. No abstract available.

PMID:
11587295
20.
21.

Prior cryopreservation of ex vivo-expanded cord blood cells is not detrimental to engraftment as measured in the NOD-SCID mouse model.

Rice AM, Wood JA, Milross CG, Collins CJ, Case J, Nordon RE, Vowels MR.

J Hematother Stem Cell Res. 2001 Feb;10(1):157-65.

PMID:
11276369
22.

Conditions that enable human hematopoietic stem cell engraftment in all NOD-SCID mice.

Rice AM, Wood JA, Milross CG, Collins CJ, McCarthy NF, Vowels MR.

Transplantation. 2000 Mar 15;69(5):927-35.

PMID:
10755552
23.

Interlaboratory variation in oxygen tension measurement by Eppendorf "Histograph" and comparison with hypoxic marker.

Nozue M, Lee I, Yuan F, Teicher BA, Brizel DM, Dewhirst MW, Milross CG, Milas L, Song CW, Thomas CD, Guichard M, Evans SM, Koch CJ, Lord EM, Jain RK, Suit HD.

J Surg Oncol. 1997 Sep;66(1):30-8.

PMID:
9290690
24.

Enhanced radioresponse of paclitaxel-sensitive and -resistant tumours in vivo.

Milross CG, Mason KA, Hunter NR, Terry NH, Patel N, Harada S, Jibu T, Seong J, Milas L.

Eur J Cancer. 1997 Jul;33(8):1299-308.

PMID:
9301459
25.

Effect of radiation and paclitaxel on p53 expression in murine tumors sensitive or resistant to apoptosis induction.

Saito Y, Milross CG, Hittelman WN, Li D, Jibu T, Peters LJ, Milas L.

Int J Radiat Oncol Biol Phys. 1997 Jun 1;38(3):623-31.

PMID:
9231689
26.

The efficacy of treatment for malignant epidural spinal cord compression.

Milross CG, Davies MA, Fisher R, Mameghan J, Mameghan H.

Australas Radiol. 1997 May;41(2):137-42.

PMID:
9153809
27.

Potentiation of antitumor efficacy of paclitaxel by recombinant tumor necrosis factor-alpha.

Seong J, Milross CG, Hunter NR, Shin HC, Milas L.

Anticancer Drugs. 1997 Jan;8(1):80-7.

PMID:
9147616
28.

The effect of tumor size on necrosis and polarographically measured pO2.

Milross CG, Tucker SL, Mason KA, Hunter NR, Peters LJ, Milas L.

Acta Oncol. 1997;36(2):183-9.

PMID:
9140436
29.

Evaluation of [131I]iodoerythronitroimidazole as a predictor for the radiosensitizing effect.

Inoue T, Yang DJ, Wallace S, Cherif A, Tansey W, Kim EE, Hunter N, Milross CG, Milas L, Podoloff DA.

Anticancer Drugs. 1996 Nov;7(8):858-65.

PMID:
8991190
30.

Relationship of mitotic arrest and apoptosis to antitumor effect of paclitaxel.

Milross CG, Mason KA, Hunter NR, Chung WK, Peters LJ, Milas L.

J Natl Cancer Inst. 1996 Sep 18;88(18):1308-14.

PMID:
8797771
31.

Therapeutic potential of paclitaxel-radiation treatment of a murine ovarian carcinoma.

Milas L, Saito Y, Hunter N, Milross CG, Mason KA.

Radiother Oncol. 1996 Aug;40(2):163-70.

PMID:
8884971
32.

Cytotoxic treatments and tumor oxygenation.

Milas L, Milross CG, Mason KA.

Cancer J Sci Am. 1996 Jan-Feb;2(1):59-60; author reply 60-1. No abstract available.

PMID:
9166500
33.

Sequence-dependent antitumor activity of paclitaxel (taxol) and cisplatin in vivo.

Milross CG, Peters LJ, Hunter NR, Mason KA, Milas L.

Int J Cancer. 1995 Sep 4;62(5):599-604.

PMID:
7665232
34.

Role of reoxygenation in induction of enhancement of tumor radioresponse by paclitaxel.

Milas L, Hunter NR, Mason KA, Milross CG, Saito Y, Peters LJ.

Cancer Res. 1995 Aug 15;55(16):3564-8.

Supplemental Content

Loading ...
Support Center